Anti-SARS-CoV-2 equine immunoglobulin fragments
- Generic Name
- Anti-SARS-CoV-2 equine immunoglobulin fragments
- Drug Type
- Biotech
Overview
Anti-SARS-CoV-2 equine immunoglobulin fragments, also known as INOSARS, is a polyvalent passive immunization being tested in the clinical trial NCT04514302 (Safety and Efficacy of Anti-SARS-CoV-2 Equine Antibody Fragments (INOSARS) for Hospitalized Patients With COVID-19). INOSARS is composed of F(ab’)2 fragments extracted from hyperimmune equine serum.
Background
Anti-SARS-CoV-2 equine immunoglobulin fragments, also known as INOSARS, is a polyvalent passive immunization being tested in the clinical trial NCT04514302 (Safety and Efficacy of Anti-SARS-CoV-2 Equine Antibody Fragments (INOSARS) for Hospitalized Patients With COVID-19). INOSARS is composed of F(ab’)2 fragments extracted from hyperimmune equine serum.
Indication
No indication information available.
Associated Conditions
No associated conditions information available.
Clinical Trials
FDA Approved Products
Singapore Approved Products
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.